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Abstract
Background: In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2
synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in
cancer prevention and treatment has been shown repeatedly; however, their clinical use is limited due to toxicity.
PGE2 signals via EP receptors 1–4, whose functions are analyzed in current research in search for targeted anti-PG
therapies. EP2 and EP4 rather promote tumorigenesis, while the role of EP3, especially in breast cancer, is not yet clear
and both pro- and anti-tumorigenic effects have been described. Our study evaluates EP3 receptor expression in
sporadic breast cancer and its association with clinicopathological parameters, progression-free and overall survival.
Methods: Two hundred eighty-nine sporadic breast cancer samples without primary distant metastasis were
immunohistochemically analyzed for EP3 receptor expression. Tissue was stained with primary anti-EP3-antibodies.
Immunoreactivity was quantified by the immunoreactivity-score (IRS); samples with an IRS≥ 2 scored as EP3 positive.
Chi-squared and Mann-Whitney-U test were used for comparison of data; Kaplan-Meier estimates and Cox-regression
were used for survival analyses.
Results: EP3 receptor was expressed in 205 of 289 samples analyzed (70.9%). EP3 receptor expression was not
associated with clinicopathological parameters (e. g. tumor size, hormone receptors, lymph node status). Kaplan-Meier
estimates showed a significant association of EP3 positivity with improved progression-free survival (p = 0.002) and
improved overall survival (p = 0.001) after up to 10 years. Cox regression analysis confirmed EP3 positivity as a
significant prognostic factor even when other known prognosticators were accounted for.
Conclusions: In sporadic breast cancer, EP3 receptor expression is not significantly associated with clinicopathological
parameters but is a significant prognostic factor for improved progression-free and overall survival. However, the
functional aspects of EP3 receptor in breast cancer and the way how EP3 may oppose the pro-tumorigenic
effects of PGE2 elevation and COX-2 overexpression are not fully understood so far. Further studies aiming at
identification of the factors regulated by EP3 are necessary to evaluate the possibility of targeting EP3 in
future anti-tumor therapy in breast cancer.
Keywords: Breast cancer, EP3, Prostaglandin E2, EP-receptor, COX-2, PGE2, Prognostic factor
* Correspondence: nina.ditsch@med.uni-muenchen.de
1Department of Obstetrics and Gynecology & Breast Center, University
Hospital, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Semmlinger et al. BMC Cancer  (2018) 18:431 
https://doi.org/10.1186/s12885-018-4286-9
Background
Breast cancer is the most common female cancer (30.8%
of all newly diagnosed cancers in women in Germany,
2012) and also the most common cause of cancer-related
death in women [1]. The development of treatment from
conventional to targeted anti-tumor therapies, e. g. human
epidermal growth factor receptor 2 (HER2) blockade, has
contributed much to improve breast cancer therapy [2].
However, as these therapies are not suitable for all pa-
tients, the search for new, individualized and specific alter-
natives of treatment is ongoing.
Eicosanoides, which include leukotriens and prosta-
glandins (PG), are tissue hormones that can act in an
autocrine or paracrine manner. They contribute to un-
countable physiological and pathological processes: The
balance of thromboxane A2 and prostacyclin e. g. is es-
sential for hemostasis, whereas PGE2 is the most abun-
dant prostaglandin in humans and is known as a key
mediator in inflammation. Cyclooxygenase (COX) en-
zymes are the primary enzymes in the synthesis of eico-
sanoides and exist in two isoforms: COX-1 is considered
to be ubiquitously expressed, whereas COX-2 is nor-
mally absent from most human tissues. COX-2 upregu-
lation can be elicited by various cytokines and growth
factors and is involved in the regulation of the inflamma-
tory response. Both COX-enzymes catalyze the conver-
sion of arachidonic acid to PGG2 and subsequently to
PGH2, which itself is the precursor molecule for the
synthesis of the different eicosanoids, including PGE2,
prostacyclin or thromboxane A2 [3, 4].
Besides its known essential function in physiological
processes and inflammation, PGE2 plays an important
role in tumorigenesis: In various cancer samples, ele-
vated PGE2 levels have been found. Similarly, constitu-
tive COX-2 overexpression - which is thought to be
responsible for the increase in PGE2 levels - has been
detected in various tumors [5]. Both increased PGE2 and
COX-2 overexpression have been associated with
tumorigenesis and progression [3, 6]. Therefore, the role
of prostaglandins and their mediators in tumorigenesis
and their potential as possible therapeutic targets have
come into focus of recent research [4, 7].
In breast cancer, COX-2 overexpression is found in
about 40% of all cases, it is inversely associated with sur-
vival rates and is positively associated with various char-
acteristics of aggressive disease [3, 6]. Studies in murine
and human breast cancer models have shown the influ-
ence of COX-2 overexpression on breast tumor develop-
ment, e. g. via the mechanisms of inducing angiogenesis
or improving cell mobility and invasiveness [8, 9].
Experimental blockade of COX-2 in a mouse model has
reduced tumor progression [10]. Similarly, COX-2 antag-
onist (COXib) treatment in humans has shown an im-
pressive preventive effect with a significant reduction in
the risk of breast cancer in a case control study [11].
These strikingly beneficial effects of inhibiting COX-2
show the potential of the COX-2-PGE2-axis in breast
cancer prevention and therapy. Unfortunately, the use of
COXibs in clinical practice is limited due to their strong
cardiovascular toxicity (thrombosis, atherogenesis, hyper-
tension). The side effects are thought to be caused by the
selective depression of prostacyclin synthesis (via COX-2
inhibition), whereas thromboxane A2 synthesis via COX-1
is not influenced and in consequence, the balance between
pro- and antithrombotic agents is disturbed [3]. Therefore,
elucidating the role of other components involved in the
exertion of PGE2-effects in search for targeted breast can-
cer therapies with lesser side effects has come into focus
of research.
PGE2 mediates its effects via four G-protein coupled
receptors, the EP receptors 1–4 with different intracellu-
lar signaling pathways [4, 12]. EP2 and EP4 receptor are
coupled to Gs-protein/protein kinase A/adenylate cy-
clase and induce intracellular elevation of cyclic adeno-
sine monophosphate (cAMP). EP1 receptor is associated
to Gq-protein and mediates elevation of intracellular
calcium and phospholipase C activation [7, 12]. As a
remarkable feature, EP3 (Prostaglandin E2 receptor 3)
exists in multiple isoforms (generated by alternative
mRNA splicing); eight different isoforms are identified
in humans and three isoforms in mice signaling via dif-
ferent G-proteins. Most human EP3 isoforms inhibit
cAMP generation via Gi-protein (on the contrary to EP2
and EP4 which increase cAMP levels), some isoforms
can also increase intracellular calcium like EP1, some
might also signal via Gs proteins [4].
EP1–4 receptor expression has been shown in a variety
of cancers, including breast cancer [13–15]. Exploiting
the role of EP receptors in breast cancer tumorigenesis,
it has been found that in COX-2-induced murine
mammary tumors, EP1, 2 and 4 are strongly induced
compared to normal mammary gland tissue, whereas
EP3 receptor expression is rather downregulated, but
still detectable [8]. However, concerning the prognostic
relevance of EP receptor expression and the effects of re-
ceptor blockade or stimulation on breast cancer devel-
opment and the course of clinical disease, studies partly
show different effects (reviewed in [4, 7] and [16]). Most
data is available concerning EP2 and EP4, whose
elevated expression in mammary tumor cells is mostly
associated with enhanced metastasis, tumor cell prolifer-
ation and tumor invasiveness [13, 14, 17]. Limited data
is available concerning EP1 in breast cancer: It has been
associated with tumor development [7, 18], but another
study associated EP1 expression with suppression of me-
tastasis while it had no effect on the primary tumor and
EP1 positive patients had improved survival [19]. There-
fore, EP1 might have a pro-tumorigenic effect on the
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primary tumor but might also have anti-metastatic ef-
fects in breast cancer [19]. Of the EP receptors, EP3 is
the least well-understood in breast cancer with both
tumor-promoting and suppressive effects having been
published [4].
As EP3 seems to have a different role than the other
EP receptors – EP3 is downregulated in tumor cells and
shows rather inhibitory signaling mechanisms – it is
suggesting that EP3 might have a protective role in
mammary tumor development and its expression on
cancer cells might be associated with a more favorable
course of the disease. This makes EP3 an interesting
target to analyze and might also open the possibility to
target EP3 in future specific cancer therapy.
To our knowledge, no sufficient data exists concerning
prognostic relevance of EP3 in sporadic breast cancer.
Therefore, we performed this study to evaluate the expres-
sion of EP3 receptor in sporadic breast cancer and its as-
sociation with clinicopathological parameters (tumor size,
lymph node status, focality, grading, hormone receptors,
HER2-amplification, age), progression and survival.
Methods
Patients
In this study, 320 consecutive patients who under-
went surgery for breast cancer from 2000 to 2002 at
the Department of Gynaecology and Obstetrics, Ludwig-
Maximilians-University of Munich, Germany and of
which tumor tissue was still available were included. Only
cases with a diagnosis of sporadic breast cancer without
family history for breast cancer were included. Patients
with primary distant metastasis were excluded from
further analysis. The histological type and tumor grading
(according to the Elston-Ellis system) was assigned by the
institute of pathology, Ludwig-Maximilians-University of
Munich; tumors were classified according to the TNM
staging system. Patient data regarding patient age, hor-
mone receptor status (estrogen receptor [ER], progester-
one receptor [PR]), HER2-amplification, metastasis, local
recurrence, progression and survival were retrieved from
the Munich Cancer Registry.
Progression-free and overall survival was statistically
analyzed after an observation period of up to 10 years.
Immunohistochemistry
Directly after resection, breast cancer tissue specimens
were fixated in formalin solution and were then embedded
in paraffin. Immunohistochemistry was performed as de-
scribed previously [20]. Primary anti-EP3-antibodies (poly-
clonal rabbit IgG, Abcam, Cambridge, UK) were used for
tissue slide staining and detected via polymer-method
(ZytoChem Plus HRP Polymer System mouse/rabbit,
Zytomed Systems Berlin, Germany) and the chromogen
diaminobenzidine (Dako, Hamburg, Germany). Placenta
tissue served as positive control, normal serum served as a
negative control. Samples were then analyzed by the
semi-quantitative immunoreactivity score (IRS) using a
Leitz (Wetzlar, Germany) microscope. The IRS multi-
plies the intensity of the staining (0 = no, 1 = weak, 2 =
moderate, 3 = strong staining) with the percentage of
positive cells (0 = no staining, 1 = < 10% positive cells, 2
= 11–50% positive cells, 3 ≥ 50% positive cells). Accord-
ing to their IRS, samples were then classified as EP3
positive or EP3 negative: Samples with an IRS of 0 or 1
were counted as EP3 negative, samples with an IRS of 2
or higher were counted as EP3 positive. Both groups
were then compared for clinicopathological parameters,
progression-free and overall survival.
Statistics
IBM SPSS software version 24 was used to analyze data.
MicrosoftExcel 2010 was used for illustrations. P-values
≤0.05 were considered statistically significant. Chi-
squared test was used to determine independence be-
tween nominal data, Mann-Whitney-U test was used to
analyze continuous variables. Kaplan-Meier estimates
were used to estimate progression-free and overall sur-
vival in EP3 positive and EP3 negative patient groups;
survival distributions were compared by the log-rank-
test. Cox regression analysis was performed to account
for effects of further variables. In the multivariate ana-
lysis, we included EP3 expression and patient age and
other clinicopathological factors which had shown p-
values ≤0.10 in bivariate survival analyses. These were
namely tumor size, lymph node status, ER, PR and
HER2 for overall survival and tumor size, lymph node
status and ER for progression free survival. Assumptions
of the Cox regression, namely non-informative censoring
and proportional hazards, were met in all analyses.
Results
Patient characteristics
From the 320 consecutive patients included in this
study, successful EP3 staining and sufficient follow-up
data could be obtained from 289 patients. Median pa-
tient age was 58 years (range 69). 49.8% of all patients
had carcinoma of no special type (NST). 70.9% of all pa-
tients had a G1 or G2 tumor, however, tumor grading
could only be obtained in 151/289 patients and the in-
fluence of this parameter therefore has to be regarded
with limited reliability. Because of limited data we did
also decide not to include grading in Cox regression
analyses. The majority of patients had a breast tumor
smaller than 2 cm in size (pT1: 67.1%, pT2: 28.4%, pT3:
1%, pT4 3.4%) and most patients did not have primary
lymph node metastasis (pN0: 57.5% of all patients).
However, 42.5% of all patients had lymph node metasta-
sis, 47.8% of all had more than one focus. Most patients
Semmlinger et al. BMC Cancer  (2018) 18:431 Page 3 of 9
were positive for ER (81%) and PR (58.8%). HER2 was
not amplificated in 87.5% of all patients. Patient charac-
teristics are displayed in Table 1. Total patient numbers
in each subgroup differ because information regarding
each subgroup could not be obtained from each patient.
Follow-up data could be obtained from 147/289 pa-
tients for the complete observation period of 10 years
with a median follow-up for the whole cohort of 10 years
(range 9.92 years).
EP3 staining is independent of clinicopathological
parameters
EP3 staining was positive in 70.9% (205/289) breast cancer
tissue sections. Examples of tissue sections stained for EP3
are displayed in Fig. 1, displaying one sample with low
(Fig. 1a) and one sample with high (Fig. 1b) percentage of
EP3 positive cells. Furthermore, positive (Fig. 1c) and
negative (Fig. 1d) staining controls are shown.
No associations of EP3 expression with clinicopatho-
logical parameters (which are listed in Table 1) were
found. EP3 expression could be shown in all histological
subtypes of breast cancer. Patient age at diagnosis did
not differ between EP3 positive and EP3 negative patient
groups (median age 59 years in EP3 negative and 57.
7 years in EP3 positive patients, p = 0.286). EP3 staining
was not associated with tumor size (≤ 2 cm vs. > 2 cm,
p = 0.394), primary lymph node metastasis (pN0 vs.
pN1–3, p = 0.132) the histological subtype of the tumor
(NST vs. non NST, p = 0.970), tumor grade (G1-G2 vs.
G3, p = 0.944) or with the number of tumor foci (unifo-
cal vs. more than one focus, p = 0.977). EP3 staining was
also not associated with positivity for the hormone
receptors ER (p = 0.188) or PR (p = 0.227) or with
HER2-amplification (p = 0.716). The distribution of EP3
staining patterns in relation to the different clinicopath-
ological parameters (histology, focality, hormone recep-
tors, HER2-amplification, tumor size, lymph node
status, grading, age) is displayed in Table 2.
EP3 receptor positivity is significantly associated with
improved progression-free survival
Overall, 111 of 289 patients showed progression-free
survival after 10 years. 115 of 289 patients suffered from
progression during the observation period; for 63 patients,
follow-up ended earlier than 10 years. In EP3 negative pa-
tients, progression occurred in 45 of 84 patients, while 70
of 205 patients had progressive disease in EP3 posi-
tive cases. Kaplan-Meier analysis estimated a 10 years
progression-free survival rate of 61% in EP3 positive
but only 43% in EP3 negative cases (Fig. 2a, p = 0.
002); so EP3 positivity was significantly associated
with improved progression-free survival. Progression-
free survival functions including progression-free sur-
vival rates and p-values are displayed in Fig. 2a.
Regarding the distribution of distant metastasis and
local recurrence as distinct manifestations of progres-
sion, the analyzed collective was similar to known
collectives of patients with sporadic breast cancer.
Kaplan-Meier analysis estimated a 10-year rate of dis-
tant metastasis of 26% in EP3 positive but 41% in
EP3 negative patients (p = 0.012). Similarly, EP3 recep-
tor expression was adversely associated with local re-
currence after 10 years (estimated local recurrence
rate of 15% in EP3 positive vs. 28% in EP3 negative
cases, p = 0.016). The difference in progression-free
survival between EP3 positive and EP3 negative patients
could thus be confirmed in both main parameters of pro-
gression, metastasis as well as local recurrence. Kaplan-
Meier-estimates of distant metastasis and local recurrence
are shown in (see Additional file 1: Figure S1).
EP3-receptor positivity is significantly associated with
improved overall survival
Overall, 147 of 289 patients were alive after 10 years.
78 of 289 patients died during the observation period;
follow up ended earlier than 10 years for 64 patients.
In EP3 negative cases, 35 deaths occurred (of 84 pa-
tients); in EP3 positive patients, 43 of 205 patients
died. The estimated overall-survival rate after 10 years
by Kaplan-Meier analysis was 76% in EP3 positive but
only 55% in EP3 negative cases (p = 0.001, Fig. 2b); so
EP3 positivity was significantly associated with im-
proved overall survival.
Overall survival functions including overall survival
rates and p-values are displayed in Fig. 2b.
Table 1 Patient characteristics
n (%) n (%)
histology tumor grade
NST 144 (49.8) G1-G2 107 (70.9)
non NST 145 (50.2) G3 44 (29.1)
tumor foci PR
unifocal 151 (52.2) negative 119 (41.2)
≥ 2 foci 138 (47.8) positive 170 (58.8)
pT HER2
pT1 193 (66.8) negative 246 (87.5)
pT2-pT4 96 (33.2) positive 35 (12.5)
pN age (years)
pN0 165 (57.5) median 58.0
pN1-pN3 122 (42.5) range 69
ER
negative 55 (19.0)
positive 234 (81.0)
NST no special type, ER estrogen receptor, PR progesteron receptor
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EP3-receptor expression is a significant prognosticator for
overall survival and progression-free survival
To determine the prognostic relevance of EP3-receptor
expression when other prognosticators were taken into
account, we performed multivariate Cox regression ana-
lysis as described above (methods, statistics).
EP3-receptor positivity was observed to be a prognos-
tic factor for improved progression-free survival (p = 0.
003, hazard ratio [HR] = 1.81, 95% confidence interval
[CI] 1.22–2.67) and improved overall survival (p = 0.002,
HR = 2.16, 95% CI 1.32–3.53) even when the effects of
further prognostic variables (named in Table 3) were
accounted for. Besides EP3 positivity, a tumor size
smaller than 2 cm and ER positivity were further prog-
nostic factors associated with advanced progression-free
and overall survival in the multivariate analysis. Add-
itionally, patient age (continuous) and PR positivity were
prognostic factors for overall survival. Data of the multi-
variate analysis is shown in Table 3. Schoenfeld residuals
of EP3 are shown in Additional file 2: Figure S2.
Discussion
Data from literature show COX-2 overexpression in
breast cancer resulting in elevated PGE2 synthesis which
is thought to contribute to disease progression. Recent
studies have evaluated the mechanisms through which
PGE2 exerts its effects in tumorigenesis and have shown
that the expression of PGE2 receptors EP1–4 is modified
in different kinds of cancer. EP2 and EP4 expression is
rather associated with an unfavorable outcome, whereas
data regarding the role of the other EP receptors EP1
and EP3, especially in breast cancer, is still sparse [4].
However, as EP3 has the unique feature that it mainly
signals via an inhibitory pathway (EP2 and EP4 on the
contrary activate a stimulatory pathway), its role in
breast cancer and its eligibility as a possible therapeutic
target should not be neglected.
This study was performed to analyze the prognostic
relevance of EP3 receptor expression in sporadic breast
cancer and its association with clinicopathological tumor
characteristics (e. g. tumor size, lymph node status, hor-
mone receptors, histology).
We have confirmed that in the majority of sporadic
breast cancer cases, EP3 receptor was expressed like it
was shown e. g. for different inflammatory breast cancer
cell lines [21]. EP3 expression occurred in all histological
subtypes of breast cancer and the expression did not dif-
fer between the histological subtypes. Therefore, target-
ing EP3 diagnostically or therapeutically seems generally
possible and could be applied to any histological breast
cancer subtype. However, EP3 expression was not com-
pared between healthy tissue and tumor – published
a b
c d
Fig. 1 EP3 expression in breast cancer. Exemplary immuno-histochemical EP3 staining of breast cancer tissue samples is displayed. a Percentage
of EP3 positive cells < 50%. b Percentage of EP3 positive cells > 50%. c Positive control (placenta). d Negative control (normal serum)
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studies have shown a downregulation of EP3 in breast
cancer compared to healthy breast tissue [8], in colon
cancer [22] and in prostate cancer [23].
EP3 receptor expression was independent of other
clinicopathological factors (named in Table 1) which
partly have known prognostic relevance (like e.g. ER-
positivity). COX-2 overexpression in breast cancer on
the contrary is mostly associated with clinicopathological
factors characteristic for an aggressive phenotype, like
large tumor size, negative hormone receptor status or
high proliferation [6, 24]. Other studies, however, did
not show an association of COX-2 overexpression with
clinicopathological parameters [25, 26].
Interestingly, EP3 receptor expression was not associ-
ated with an unfavorable course of the disease, like it is
known e. g. from EP2 and EP4 [13, 14, 17, 27]. On the
contrary, instead of a negative influence of EP3, an
association of EP3 with improved survival and improved
progression-free survival could be shown. EP3 was even
a significant prognostic factor when other factors with
known prognostic influence were accounted for (Table 3).
To our knowledge, this is the first report of EP3 as a
prognosticator for survival or progression-free survival
in breast cancer.
Data concerning EP3 in breast cancer is sparse. EP3 is
described as irrelevant in one study, where treatment of
breast cancer cells with EP3 antagonists had no effect on
metastasis [15]. Another study in inflammatory breast
cancer, however, showed a beneficial effect of EP3, as
treatment of inflammatory breast cancer cells with the
EP3 agonist sulprostone reduced the ability of the tumor
cells to undergo vasculogenic mimicry, a characteristic
of very aggressive tumor types [21].
Regarding the role of EP3 in other cancer types, both
pro- and anti-tumorigenic effects have been described.
Some data suggest a pro-tumorigenic effect of EP3
receptor expression, as EP3 has been associated to
angiogenesis and lymphangiogenesis: When Lewis lung
carcinoma cells were injected in mice, tumor-associated
angiogenesis, metastasis and tumor growth were reduced
in EP3 knockout mice compared to wild type mice. Also,
levels of vascular endothelial growth factor, matrix-
metalloproteinase-9 and of podoplanin, a marker for
lymphatic endothelial cells, were reduced in EP3 knock-
out mice and induced by EP3 agonists [28–30].
Other studies, on the contrary, suggest an anti-
tumorigenic effect of EP3 receptor expression. EP3
knockout e.g. enhanced azoxymethane-induced colon
carcinogenesis [22] and contributed to squamous cell car-
cinoma development [31]. Similarly, EP3 knockdown in
prostate cancer cells or treatment of prostate cancer cells
with EP3 antagonists accelerated tumor cell growth [32].
Consistent with this data, EP3 overexpression in prostate
cancer cells impaired tumor growth in vitro and stimula-
tion of cells overexpressing EP3 with the EP3 agonist
sulprostone further enhanced the inhibitory effect [23].
Therefore, the authors of these studies hypothesize that the
reduction of EP3 expression during tumorigenesis might
be consistent with tumor-suppressive properties of EP3.
Differences between the above named studies might
be partly due to the different EP3 isoforms, as EP3 iso-
forms mainly signal via Gi proteins but partly also via
the Ca2+/phospholipase cascade or via Gs proteins [4].
Therefore, different effects in studies concerning EP3
might be to some extent due to different expression
patterns of the isoforms. In prostate cancer e.g., EP3 II, an
EP3 isoform coupled to Gi protein, was the major isoform
found and EP3-expression also showed inhibitory effects
on tumor cell growth in this study [23]. In mice, three
EP3 isoforms exist and overexpression of all three variants
has been associated with reduced tumor cell growth [33].
Table 2 Distribution of EP3 staining patterns
EP3 negative EP3 positive
n (%) n (%) p-value
histology
NST 42 (14.5) 102 (35.3)
non NST 42 (14.5) 103 (35.6) 0.970
tumor foci
unifocal 44 (15.2) 107 (37.0)
≥ 2 foci 40 (13.8) 98 (33.9) 0.977
tumor grade
G1-G2 31 (20.5) 76 (50.3)
G3 13 (8.6) 31 (20.5) 0.944
pT
pT1 53 (18.3) 140 (48.4)
pT2-pT4 31 (10.7) 65 (22.5) 0.394
pN
pN0 42 (14.6) 123 (42.9)
pN1-pN3 41 (14.3) 81 (28.2) 0.132
ER
negative 12 (4.2) 43 (14.9)
positive 72 (24.9) 162 (56.1) 0.188
PR
negative 30 (10.4) 89 (30.8)
positive 54 (18.7) 116 (40.1) 0.227
HER2
negative 70 (24.9) 176 (62.6)
positive 11 (3.9) 24 (8.5) 0.716
age (years)
median 59.0 57.7
range 62 60 0.286
NST no special type, ER estrogen receptor, PR progesterone receptor
Semmlinger et al. BMC Cancer  (2018) 18:431 Page 6 of 9
For future studies in breast cancer it is therefore necessary
to clarify which isoforms are expressed in which manner
to better understand the effects and to facilitate compar-
ing different studies.
In summary, our study has shown that in breast
cancer, EP3 was a significant prognosticator for im-
proved progression-free and overall survival without
association of its expression to known clinicopatho-
logical parameters. This is contrary to part of the
above named studies, where EP3 has shown negative
effects and is also contrary to the negative effects of
the other EP receptors (EP2, EP4) in breast cancer
[4]. The positive prognostic influence of EP3 in breast
cancer is surprising insofar, as both COX-2 overex-
pression and PGE2 elevation have been shown to have
pro-tumorigenic effects in breast cancer, and EP3 is
part of the signaling pathway of PGE2 and is there-
fore mediating PGE2 effects. As EP3 seems to have a
beneficial effect in breast cancer, it is likely, that one
or more of the functional effects of PGE2 in tumori-
genesis (proliferation, invasiveness, metastasis, anti-
apoptotic effect) might be inhibited by EP3. Our
future work will concentrate on identification of the
factor that is regulated by EP3. By improving the un-
derstanding of the functional aspects of EP3 and its
regulated factors, we aim to evaluate its eligibility as
Table 3 Multivariate Cox regression analysis of progression-free and overall survival
Covariate Progression-free survival Overall survival
95 % CI 95 % CI
Coefficient HR Lower Upper p-value Coefficient HR Lower p-value
(B) Exp(B) (B) Exp(B)
age (continous, unit: 1 year) 0.008 1.009 0.99 1.02 0.254 0.04 1.04 1.02 1.06 *<0.001
pT2-4, reference category: pT1 -0.879 0.42 0.28 0.62 *<0.001 -1.17 0.31 0.19 0.52 *<0.001
pN1-3, reference category: pN0 -0.21 0.81 0.53 1.23 0.323 -0.44 0.64 0.38 1.10 0.107
ER pos, reference category: ER neg 0.52 1.69 1.08 2.63 *0.021 0.75 2.11 1.19 3.74 *0.011
PR pos, reference category: ER neg n.i. 0.56 1.75 1.03 2.98 *0.040
HER2 pos, reference category: HER2 neg n.i. -0.57 0.57 0.31 1.04 0.067
EP3 pos, reference category: EP3 neg 0.59 1.81 1.22 2.67 *0.003 0.77 2.16 1.32 3.53 *0.002
number of samples 275 275
number of events 108 72
HR hazard ratio, CI confidence interval, Pos positive, Neg negative, n.i. not included in multivariate model, as p>0.10 in bivariate analysis, *statistically
significant (p-value < 0.05)
a b
Fig. 2 Overall survival and progression-free survival in sporadic breast cancer. Kaplan-Meier estimates of overall probability of survival (b) and
probability of progression-free survival (a) of EP3 positive and negative patient groups are displayed. Estimated survival rates are displayed at the
end of each graph, p-values in the lower left corner. EP3 positivity was significantly associated with improved probability of progression-free
survival (a) and improved overall probability of survival (b). yrs.: years, neg: negative, pos: positive
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a possible future target in breast cancer prevention
and treatment.
Conclusions
In conclusion, this study shows that EP3-receptor is a sig-
nificant prognosticator for improved progression-free and
overall survival in sporadic breast cancer. This opens the
possibility to use EP3 as a prognostic factor but also to fur-
ther examine it as a target for future specific anti-tumor
therapies. Therefore, the mechanisms how EP3 suppresses
tumor progress have to be evaluated in future research.
Additional files
Additional file 1: Figure S1. Metastasis and local recurrence in sporadic
breast cancer. 10-years Kaplan-Meier-estimates of cumulative metastasis (A)
and cumulative local recurrence (B) of EP3 positive and negative patient
groups are displayed. Estimated metastasis and local recurrence rates are
displayed at the end of each graph, p-values in the upper left corner. EP3
positivity was significantly associated with reduced metastasis (A) and local
recurrence (B). Note that in the rates of metastasis and local recurrence
named there, all cases of metastasis/local recurrence are considered,
regardless if they were the primary cause of progression or happened later
in the course of disease; therefore, the sum of both rates here is higher than
the progression rate named in Fig. 2. yrs. = years. (PDF 437 kb)
Additional file 2: Figure S2. Schoenfeld residuals for EP3. To test for PH
assumption, Schoenfeld residual test was performed for EP3 for OS and
PFS. Schoenfeld residuals for EP3 are displayed (left: OS, right: PFS). There
is no violation of PH assumption, as the ratio of both curves is stable
over the time. (PDF 20 kb)
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